Dexamethasone in a small patient population (severe patients with a number of exclusion criteria).

Itolizumab was open label.

“Trust us... the treatment patients were just as sick and the statistical significance kicked ass in the 30 patient trial”

Don’t worry, they are “planning” a double blinded, random assorted placebo controlled study.

Perhaps something like the ones being co ducted here.